Alzheimer’s disease, frontotemporal dementias, progressive supranuclear palsy, Corticobasal degeneration, Clinical Trial Study
< Back to Find a Trial

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy (M15-562)

ID
NCT02985879
Condition Studied
Progressive Supranuclear Palsy
Phase
Phase II
Status
Closed
Intervention
ABBV-8E12
Principal Investigator
Sponsor
AbbVie

Please go to ClinicalTrials.gov for more information.